These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 31325305)

  • 1. Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review.
    Schlager L; Loiskandl M; Aletaha D; Radner H
    Rheumatology (Oxford); 2020 Feb; 59(2):324-334. PubMed ID: 31325305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study.
    Yoshida K; Radner H; Mjaavatten MD; Greenberg JD; Kavanaugh A; Kishimoto M; Matsui K; Okada M; Reed G; Saeki Y; Tohma S; Kremer J; Solomon DH
    J Rheumatol; 2015 Dec; 42(12):2238-46. PubMed ID: 26523025
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discontinuation of biologic DMARDs in a real-world population of patients with rheumatoid arthritis in remission: outcome and risk factors.
    Arnold S; Jaeger VK; Scherer A; Ciurea A; Walker UA; Kyburz D
    Rheumatology (Oxford); 2021 Dec; 61(1):131-138. PubMed ID: 33848332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doppler ultrasound predicts successful discontinuation of biological DMARDs in rheumatoid arthritis patients in clinical remission.
    Terslev L; Brahe CH; Hetland ML; Georgiadis S; Ellegaard K; Juul L; Huynh T; Døhn UM; Fana V; Møller T; Krabbe S; Ørnbjerg LM; Glinatsi D; Røgind H; Hansen A; Nørregaard J; Jacobsen S; Jensen DV; Manilo N; Asmussen K; Boesen M; Rastiemadabadi Z; Morsel-Carlsen L; Møller JM; Krogh NS; Østergaard M
    Rheumatology (Oxford); 2021 Dec; 60(12):5549-5559. PubMed ID: 33748831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Singapore Chapter of Rheumatologists updated consensus statement on the eligibility for government subsidization of biologic and targeted-synthetic therapy for the treatment of rheumatoid arthritis.
    Leong JWY; Cheung PP; Dissanayake S; Fong WWS; Leong KH; Leung YY; Lim AYN; Lui NL; Manghani M; Santosa A; Sriranganathan MK; Suresh E; Tan TC; Teng GG; Lahiri M
    Int J Rheum Dis; 2020 Feb; 23(2):140-152. PubMed ID: 31859424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
    Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
    Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease-modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study.
    Kaban N; Harman H
    Int J Rheum Dis; 2023 Apr; 26(4):689-698. PubMed ID: 36807751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.
    Henaux S; Ruyssen-Witrand A; Cantagrel A; Barnetche T; Fautrel B; Filippi N; Lukas C; Raffeiner B; Rossini M; Degboé Y; Constantin A
    Ann Rheum Dis; 2018 Apr; 77(4):515-522. PubMed ID: 29187350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review.
    Tweehuysen L; van den Ende CH; Beeren FM; Been EM; van den Hoogen FH; den Broeder AA
    Arthritis Rheumatol; 2017 Feb; 69(2):301-308. PubMed ID: 27696778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors at diagnosis for start of biologic disease-modifying antirheumatic drugs in patients with early rheumatoid arthritis: a cohort study.
    Hameed M; Exarchou S; Eberhard A; Sharma A; Bergström U; Cagnotto G; Einarsson JT; Turesson C
    BMJ Open; 2024 Feb; 14(2):e076131. PubMed ID: 38382962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A real-world 2-year prospective study of medication tapering in patients with well-controlled rheumatoid arthritis within the rheumatoid arthritis medication tapering (RHEUMTAP) cohort.
    Tageldin M; Wilson N; Yin Y; Sharma TS
    Rheumatology (Oxford); 2023 Oct; 62(Suppl_4):iv8-iv13. PubMed ID: 37855679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of biologic discontinuation due to insufficient response in patients with rheumatoid arthritis who achieved clinical remission with biologic treatment: A multicenter observational cohort study.
    Asai S; Fujibayashi T; Oguchi T; Hanabayashi M; Hayashi M; Matsubara H; Ito T; Yabe Y; Watanabe T; Hirano Y; Kanayama Y; Kaneko A; Kato T; Takagi H; Takahashi N; Funahashi K; Takemoto T; Asai N; Watanabe T; Ishiguro N; Kojima T
    Mod Rheumatol; 2018 Mar; 28(2):221-226. PubMed ID: 28701065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with discontinuation of biologics in patients with inflammatory arthritis in remission: data from the BIOBADASER registry.
    Valero M; Sánchez-Piedra C; Freire M; Colazo M; Busquets N; Meriño-Ibarra E; Rodríguez-Lozano C; Manrique S; Campos C; Sánchez-Alonso F; Castrejón I
    Arthritis Res Ther; 2023 May; 25(1):86. PubMed ID: 37217997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and causes of first-line biologic agent discontinuation in rheumatoid arthritis: data from Reuma.pt.
    Gomes JL; Sepriano A; Eusébio M; Serra S; Fonseca JE; Saavedra MJ; Cunha-Miranda L; Silva C; Bernardes M; Rosa-Gonçalves D; Costa J; Castelão W; Branco JC; Santos MJ
    Acta Reumatol Port; 2019; 44(1):57-64. PubMed ID: 31249276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasonographic Efficacy of Biologic and Targeted Synthetic Disease-Modifying Antirheumatic Drug Therapy in Rheumatoid Arthritis From a Multicenter Rheumatoid Arthritis Ultrasound Prospective Cohort in Japan.
    Nishino A; Kawashiri SY; Koga T; Iwamoto N; Ichinose K; Tamai M; Nakamura H; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Hamada H; Tsuru T; Nagano S; Arinobu Y; Hidaka T; Kawakami A
    Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1719-1726. PubMed ID: 29481732
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tapering and Discontinuation of Biologics in Patients with Psoriatic Arthritis with Low Disease Activity.
    Ye W; Tucker LJ; Coates LC
    Drugs; 2018 Nov; 78(16):1705-1715. PubMed ID: 30341684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of treatments for rheumatoid arthritis in clinical practice: A systematic review.
    Sparks JA; Harrold LR; Simon TA; Wittstock K; Kelly S; Lozenski K; Khaychuk V; Michaud K
    Semin Arthritis Rheum; 2023 Oct; 62():152249. PubMed ID: 37573754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.
    McDermott GC; DiIorio M; Kawano Y; Jeffway M; MacVicar M; Dahal K; Moon SJ; Seyok T; Coblyn J; Massarotti E; Weinblatt ME; Weisenfeld D; Liao KP
    Semin Arthritis Rheum; 2024 Jun; 66():152421. PubMed ID: 38457949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Sesin CA; Bingham CO
    Semin Arthritis Rheum; 2005 Dec; 35(3):185-96. PubMed ID: 16325659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.